1-二苯甲基-4-(3-氯丙基)哌嗪 | 75591-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-二苯甲基-4-(3-氯丙基)哌嗪
• 英文名称: 1-(3-chloropropyl)-4-benzhydrylpiperazine
• 英文别名: 4-(3-chloro-1-propyl)-1-(diphenylmethyl)piperazine；1-[4-(diphenylmethyl)piperazinyl]-3-chloropropane；1-benzhydryl-4-(3-chloro-propyl)piperazine；1-(3-chloropropyl)-4-(diphenylmethyl)piperazine；4-benzhydryl-1-(3-chloropropyl)piperazine；1-Benzhydryl-4-(3-chloropropyl)piperazine
• CAS: 75591-22-9
• 化学式: C₂₀H₂₅ClN₂
• 分子量: 328.885
• InChiKey: NSIZVHLMDWKOGG-UHFFFAOYSA-N

物化性质

• 沸点：
  436.2±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-二苯甲基-4-(3-氯丙基)哌嗪 在 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-(diphenylmethyl)-1-piperazinepropanamine
  参考文献：
  名称：

  氢化吖啶衍生物及其应用

  摘要：

  本发明涉及化学合成领域，特别涉及通式为Y-L-X的化合物及其作为钙通道阻滞剂或/和乙酰胆碱酯酶抑制剂的应用。通式为Y-L-X的化合物可以调节钙体内稳态、治疗心血管疾病、中风或痴呆。

  公开号：

  CN103524413B
• 作为产物：
  描述：

  二苯甲基哌嗪 在 氯化亚砜 、 potassium carbonate 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 1-二苯甲基-4-(3-氯丙基)哌嗪
  参考文献：
  名称：

  氢化吖啶衍生物及其应用

  摘要：

  本发明涉及化学合成领域，特别涉及通式为Y-L-X的化合物及其作为钙通道阻滞剂或/和乙酰胆碱酯酶抑制剂的应用。通式为Y-L-X的化合物可以调节钙体内稳态、治疗心血管疾病、中风或痴呆。

  公开号：

  CN103524413B

文献信息

• Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis
  作者：Malkeet Kumar、Kawaljit Singh、Andile H. Ngwane、Fahreta Hamzabegovic、Getahun Abate、Bienyameen Baker、Ian Wiid、Daniel F. Hoft、Peter Ruminski、Kelly Chibale

  DOI：10.1016/j.bmc.2017.12.047

  日期：2018.2

  Novel reversed isoniazid (RINH) agents were synthesized by covalently linking isoniazid with various efflux pump inhibitor (EPI) cores and their structural motifs. These RINH agents were then evaluated for anti-mycobacterial activity against sensitive, isoniazid mono-resistant and MDR clinical isolates of M. tuberculosis and a selected number of compounds were also tested ex vivo for intracellular

  通过将异烟肼与各种外排泵抑制剂（EPI）核及其结构基序共价连接，合成了新型反向异烟肼（RINH）剂。这些RINH剂然后针对敏感，异烟肼单抗性和MDR临床分离株的抗分枝杆菌活性的评估结核分枝杆菌和所选择的一些化合物还测试了离体细胞内的活性以及在溴化乙锭（EB）测定外排泵抑制功效。针对的各种菌株一些化合物的效力的结核分枝杆菌（4A - ç，7和8 ;分枝杆菌H37Rv-MIC 99 ≤1.25μM，R5401-MIC 99≤2.5微米，X_61-MIC 99 ≤5微米）证明的逆转抗结核剂战略走向新的抗分枝杆菌剂的发展，解决耐药性的迅速增长的问题的可能性。此外，对于> 90％的通过抑制巨噬细胞活性1A - Ç和图3b（MIC 90 ≤13.42μM）和EB的抑制流出证明这些化合物是令人鼓舞的。
• Isatin derivatives, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04382934A1

  公开（公告）日：1983-05-10

  A compound of the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen, halogen, lower alkyl, lower alkoxy, halo (lower) alkyl, lower alkanoylamino, lower alkoxyalylamino, or a 5 to 6 membered saturated or unsaturated heterocyclic group having at least one imino group, and selected from the group consisting of pyrrolidinyl, pyrrolinyl, imidazolidinyl, piperazinyl, piperidyl, and morpholynyl, or R.sup.1 and R.sup.2 are combined together to form a benzene ring, R.sup.3 is oxo or a group of the formula .dbd.N--OR.sup.5, in which R.sup.5 is hydrogen or lower alkyl, R.sup.4 is mono- or di- or triphenyl (lower) alkyl, A is C.sub.1 to C.sub.7 alkylene and its hydroxy derivatives, Y is (C.sub.1 to C.sub.3) alkylene, or a pharmaceutically acceptable salt thereof. Said compounds having antiallergic properties represent inclusively all of the possible optical and/or geometrical isomers due to the asymmetric carbon and carbon-nitrogen double bond.

  通用公式的化合物：##STR1##其中R.sup.1和R.sup.2是氢、卤素、较低的烷基、较低的烷氧基、卤代（较低的）烷基、较低的烷酰氨基、较低的烷氧基烷氨基，或者是至少含有一个亚胺基的5到6元饱和或不饱和杂环基，选自吡咯烷基、吡咯烯基、咪唑烷基、哌嗪基、哌啶基和吗啉基，或者R.sup.1和R.sup.2结合在一起形成苯环，R.sup.3是氧代或具有.dbd.N--OR.sup.5的基团，其中R.sup.5是氢或较低的烷基，R.sup.4是单、双或三苯基（较低的）烷基，A是C.sub.1到C.sub.7烷基及其羟基衍生物，Y是（C.sub.1到C.sub.3）烷基，或其药用可接受盐。所述具有抗过敏特性的化合物包括由于不对称碳和碳-氮双键而具有的所有可能的光学和/或几何异构体。
• DIPHENYLMETHYL PIPERAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION USING SAME
  申请人：Kaneko Noboru

  公开号：US20140296253A1

  公开（公告）日：2014-10-02

  The present invention provides: a novel compound which has a useful pharmacological action for treating heart failure or shock without increasing heart rate; and a pharmaceutical composition using the same. The present invention relates to a diphenylmethyl piperazine derivative represented by general formula (I) (In the formula, R 1 is a hydrogen atom or a hydroxy group. R 2 is a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group having one to five carbon atoms, or an alkoxyl group having one to five carbon atoms, excluding the case where R 1 is a hydroxy group and R 2 is a chlorine atom.) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.

  本发明提供了一种新型化合物，具有治疗心力衰竭或休克的有用药理作用，而不会增加心率；以及使用该化合物的药物组合物。本发明涉及一种由通式（I）表示的二苯甲基哌嗪衍生物（在该式中，R1是氢原子或羟基。R2是氢原子、卤素原子、羟基、具有一至五个碳原子的烷基或具有一至五个碳原子的烷氧基，不包括R1是羟基且R2是氯原子的情况。）或其药学上可接受的盐，以及含有该化合物的药物组合物。
• Derivatives of 1-diphenylmethyl piperazine and their use as
  申请人：Laboratorios Del Dr. Esteve, S. A.

  公开号：US05166205A1

  公开（公告）日：1992-11-24

  The present invention relates to novel derivatives of 1-diphenylmethyl piperazinyl, characterized in that they correspond to the general formula I, and their therapeutically acceptable salts, ##STR1## in which: R.sub.1 and R.sub.2, equal or different, represent a hydrogen atom, a halogen, a lower alkyl radical, a hydroxy radical, an alkoxy radical, an alkyl carboxylate radical, an aryl or substituted aryl radical, n may have the values 2 to 4, X, Y, Z and W, equal or different, represent a nitrogen atom or a carbon atom linked to a hydrogen atom, a halogen or to another alkyl, aryl, carboxyalkyl, carbonyl, hydroxyl, sulfonyl and alkylsulfonyl radical. The present invention also relates to the process of preparing these compounds and their use for the manufacture of medicaments intended for prophylaxis and for the treatment of various allergic disorders caused by histamine.

  本发明涉及1-二苯甲基哌嗪新型衍生物，其特征在于它们符合通式I，并且它们的治疗接受的盐，其中：R1和R2，相等或不同，代表氢原子、卤素、较低的烷基基团、羟基基团、烷氧基团、烷基羧酸酯基团、芳基或取代的芳基，n的值可以是2到4，X、Y、Z和W，相等或不同，代表与氢原子、卤素或另一个烷基、芳基、羧基烷基、羰基、羟基、磺酰基和烷基磺酰基基团连接的氮原子或碳原子。本发明还涉及制备这些化合物的过程以及它们用于制造用于预防和治疗由组胺引起的各种过敏性疾病的药物。
• Tricyclic triazolo derivatives, processes for producing the same and the
  申请人：Toray Industries, Inc.

  公开号：US05683998A1

  公开（公告）日：1997-11-04

  Novel tricyclic triazolo derivatives and pharmaceutically acceptable salts thereof, which are useful as anti-inflammation agents, anti-allergy agents or anti-PAF agents as well as processes for producing the same are disclosed. The triazolo derivatives of the present invention are represented by the formula (I): ##STR1## \x9bwherein R.sup.1 represents hydrogen, lower alkyl or C.sub.3 -C.sub.5 cycloalkyl; R.sup.2 and R.sup.3 respectively represent hydrogen, lower alkyl, lower alkoxy or halogen; W represents C.dbd.O or CR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 respectively represents hydrogen or lower alkyl); A represents C.sub.1 -C.sub.5 straight or branched saturated or unsaturated alkylene which may contain one or more hetero atoms; l represents 0 to 2, n represents 1 to 3, . . . represents single bond or double bond; Y represents N or C; Z represents C(B)Ar.sup.1 Ar.sup.2 (wherein B represents hydrogen, hydroxy or methoxy, Ar.sup.1 and Ar.sup.2 respectively represent hydrogen or substituted or non-substituted aryl), CAr.sup.1 Ar.sup.2 (wherein Ar.sup.1 and Ar.sup.2 represent the same meanings as mentioned above), O--CHAr.sup.1 Ar.sup.2 (wherein Ar.sup.1 and Ar.sup.2 represent the same meanings as mentioned above) or condensed aromatic ring!.

  揭示了新型三环三唑衍生物及其药用可接受盐，其可用作抗炎药物、抗过敏药物或抗PAF药物，以及生产这些化合物的方法。本发明的三唑衍生物由以下式（I）表示：其中R.sup.1代表氢、较低烷基或C.sub.3-C.sub.5环烷基；R.sup.2和R.sup.3分别代表氢、较低烷基、较低烷氧基或卤素；W代表C.dbd.O或CR.sup.4R.sup.5（其中R.sup.4和R.sup.5分别代表氢或较低烷基）；A代表可能含有一个或多个杂原子的C.sub.1-C.sub.5直链或支链饱和或不饱和烷基；l代表0至2，n代表1至3，...代表单键或双键；Y代表N或C；Z代表C（B）Ar.sup.1Ar.sup.2（其中B代表氢、羟基或甲氧基，Ar.sup.1和Ar.sup.2分别代表氢或取代或未取代芳基）、CAr.sup.1Ar.sup.2（其中Ar.sup.1和Ar.sup.2代表上述相同含义）、O-CHAr.sup.1Ar.sup.2（其中Ar.sup.1和Ar.sup.2代表上述相同含义）或缩合芳环！。